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Abstract
Introduction In December 2019, an outbreak of a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
began, resulting in a number of antivirals and immune modulators being repurposed to treat the associated coronavirus disease 
2019 (COVID-19). Many patients requiring treatment for COVID-19 may have either pre-existing renal or hepatic disease 
or experience acute renal/hepatic injury as a result of the acute infection. Altered renal or hepatic function can significantly 
affect drug concentrations of medications due to impaired drug metabolism and excretion, resulting in toxicity or reduced 
efficacy. The aim of this paper is to review the pharmacokinetics and available study data for the experimental COVID-19 
therapies in patients with any degree of renal or hepatic impairment to make recommendations for dosing.
Methods COVID-19 agents included in these recommendations were listed as primaries on the University of Liverpool 
COVID-19 drug interaction website (www.covid 19-drugi ntera ction s.org), initially identified from Clinicialtrials.gov and 
ChicCTR.org.cn. A literature search was performed using PubMed and EMBASE as well as product licences and pharma-
cokinetic databases.
Findings Remdesivir, dexamethasone, azithromycin, favipiravir, lopinavir/ritonavir, atazanavir, hydroxychloroquine, inter-
feron beta, ribavirin, tocilizumab, anakinra and sarilumab were identified as experimental drugs being used in COVID-19 
trials as of November 2020. Limited study data was found for these drugs in patients with renal or hepatic impairment for 
COVID-19 or other indications. Recommendations were made based on available data, consideration of pharmacokinetic 
properties (including variability), the dosing and anticipated treatment duration of each regimen in COVID-19 and known 
toxicities.
Conclusion Dosing of drugs used to treat COVID-19 in patients with renal or hepatic impairment is complex. These recom-
mendations were produced to provide guidance to clinicians worldwide who are treating patients with COVID-19, many of 
whom will have some degree of acute or chronic renal or hepatic impairment.
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Key Points 
Remdesivir and favipiravir should not be used in patients 
with impaired renal function and when ribavirin and 
anakinra are used in patients with impaired renal func-
tion, we would recommend dose adjustments based on 
the pharmacokinetics of these drugs.
When atazanavir and favipiravir are used for COVID-
19 treatment in patients with hepatic impairment, dose 
adjustments are recommended based on the pharmacoki-
netics. For tociluzumab, interferon beta and sarilumab, 
caution is required when used in COVID-19 patients 
with Child Pugh A/B.
Licensed recommendations of these medicines in previ-
ous non-COVID-19 settings can inform dosing choices; 
however, often the dosage used of these medicines for 
the treatment of COVID-19 varies significantly amongst 
different studies or empirical usage. Short-term use 
could be considered in some circumstances where 
license restrictions are in place.
1 Introduction
In December 2019, an outbreak of a novel severe acute res-
piratory syndrome coronavirus 2 (SARS-CoV-2) began, 
which has since become a global pandemic, significantly 
affecting human health and global economies. A number 
of antivirals and immune modulators have been repurposed 
for the treatment of COVID-19 and these experimental 
agents have been used both within and outside clinical stud-
ies. Whilst most data indicate the lungs as the main organ 
involved in the disease, data now exist showing significant 
involvement of the liver and kidneys [1, 2], which can poten-
tially impair the metabolism and excretion of the medica-
tions taken to treat the disease.
Altered renal or hepatic function can significantly affect 
drug concentrations of COVID-19 medications due to the 
impaired capacity of these organs to metabolise and excrete 
drugs. As well as altering elimination, the first pass metabo-
lism can also be affected and thus the absorption and bio-
availability of drugs. These changed pharmacokinetics can 
lead to increased or decreased exposure, resulting in either 
toxicity or reduced efficacy, which could be of clinical rel-
evance based on the therapeutic window and pharmacody-
namics of the specific drug. However, additional toxicity 
might be acceptable when the drug is effective in severe 
cases of COVID-19. In addition, the disease itself could also 
influence drug exposure.
Chronic liver disease represents a major disease burden 
with worldwide estimates showing an incidence of 844 mil-
lion people [3]. Repurposed treatments are being used to 
treat COVID-19 globally in patients with both pre-existing 
chronic liver disease and new onset acute liver injury, so 
there is a need for appropriate dosing strategies. Mortality 
and disease-related complications of patients with COVID-
19 and cirrhosis, such as hepatic encephalopathy, upper gas-
trointestinal bleeding, liver failure and secondary infection, 
are being followed up in multi-centred cohort clinical studies 
[4] but as of now few data exist in this group. Understand-
ing how pre-existing liver disease influences liver injury in 
patients with COVID-19 and consequently drug metabolism 
needs further evaluation. Overall, the incidence of elevated 
serum liver function tests (LFTs) in hospitalised patients 
with COVID-19, primarily elevated AST and ALT, and 
elevated bilirubin, ranges from 14 to 75% [5–10] in patients 
with or without pre-existing liver disease. In a multi-centre 
study in the US, 75% of 2273 patients who tested positive 
had a peak ALT greater than the upper limit of normal 
(ULN), 45% with a rise of 2× ULN indicating that acute 
liver injury is common. This is most often mild but those 
with severe liver injury had a more severe clinical course, 
including higher rates of intensive care unit (ICU) admis-
sion, intubation, renal replacement therapy and mortality 
[9]. Low albumin has also been found to be a marker of 
severe infection and poor prognosis [11]. Liver damage in 
COVID-19 patients might be caused by the viral infection 
of liver cells, by immune-associated inflammation (cytokine 
storm release of interleukin [IL]6) or pneumonia-associated 
hypoxia. Additionally, in a large population study of hos-
pitalised patients with COVID-19 in the UK, pre-existing 
liver disease was associated with an increased age-adjusted 
mortality [12].
Similar considerations are required with respect to renal 
function. Patients with COVID-19 may have pre-existing 
renal impairment due to chronic kidney disease (CKD), 
which is known to have an estimated global prevalence of 
8.5–9.8% [13]. Preliminary data from New York showed 
that of the intubated patients admitted to the ICU, 20–40% 
had acute kidney injury (AKI) requiring renal replace-
ment therapy (RRT) [14]. In Wuhan, lower numbers were 
reported: 5/138 (3.6%) patients developed AKI [15]. An 
early report from the United States described that 69% of 
COVID-19-positive patients (n = 43) developed an AKI. 
Aggarwal et al. [16] showed with a retrospective analysis 
that haematuria and proteinuria were present in 44% and 
59% of COVID-19-infected patients at admission (n = 193) 
[17]. One hypothesis is that SARS-CoV-2 directly affects the 
kidney as it uses angiotensin converting enzyme (ACE) 2 to 
target cells. This could potentially result in loss of function. 
Recommendations for dosing of repurposed COVID-19 medications
Another hypothesis is that a cytokine storm could contribute 
to impaired renal function or AKI [1, 18].
Based on these data and the high burden of pre-existing 
liver and renal disease, there is a need for evidence-based 
dosing recommendations for repurposed COVID-19 treat-
ments in these special populations who are excluded from 
many of the clinical trials. Therefore, the aim of this paper 
is to review the pharmacokinetics and available study data 
for the experimental COVID-19 therapies in patients with 
any degree of renal or hepatic impairment to make recom-
mendations for dosing in these special populations.
Despite many studies having reported both positive and 
negative outcomes for some of the drugs discussed in this 
paper, empirical use remains high in many countries with 
limited access to clinical studies. We do not comment on the 
efficacy of these agents or examine pharmacokinetic (PK) 
variability or bioavailability in liver disease due to lack of 
any pharmacokinetic/pharmacodynamic (PK/PD) data for 
any of the COVID therapies. As most of the world enters a 
second wave, higher than the first in many continents, there 
has been a further increase in the use of these repurposed 
medications, particularly in settings where there is limited 
choice of therapies available, and the need for appropriate 
dosing remains paramount.
2  Methods
2.1  Identifying COVID‑19 Therapies
Repurposed therapies for COVID-19 reviewed for these rec-
ommendations were listed as primaries on the University of 
Liverpool COVID-19 drug interaction website [19] on 15 
October 2020. The COVID-19 drug interaction website has 
been accessed in 196 countries and uses therapies selected 
for inclusion as an experimental drug therapy based on 
global use for treatment or prevention of COVID-19 within 
randomised controlled trials that are multi-country or multi-
centre within one country [20]. These were identified by 
searching ClinicialTrials.gov and ChicCTR.org.cn for the 
following search terms: COVID-19, 2019-nCoV, 2019 novel 
coronavirus, and SARS-CoV-2. PubMed was searched with 
the MeSH term ‘COVID-19’. We identified dexametha-
sone, atazanavir, lopinavir/ritonavir, remdesivir, favipiravir, 
hydroxychloroquine, azithromycin, interferon beta, ribavirin, 
tocilizumab, anakinra and sarilumab.
Given that COVID-19 drugs are unlikely to be used in 
isolation, we should also consider concomitant drugs and 
potential drug interactions [19, 21], the effect of which 
may be potentiated in renal or hepatic impairment. For the 
purpose of this review, mild, moderate and hepatic impair-
ment are referred to in line with drug licence and can be 
assumed to be Child Pugh Turcotte (CPT) score A, B and 
C, respectively. Monoclonal and polyclonal antibodies used 
in early clinical studies of SARS Cov-2 have also been 
excluded as, to date, there is nothing published on special 
populations to make recommendations on.
2.2  Identifying Hepatic and Renal 
Recommendations
A literature search was performed using PubMed and 
EMBASE to identify relevant English-language articles pub-
lished up to and including October 15, 2020. Search terms 
included COVID-19, 2019-nCoV, SARS-CoV-2, 2019 novel 
coronavirus, and SARS-CoV-2 in combination with liver 
disease/impairment, cirrhosis and decompensation to iden-
tify peer-reviewed studies containing information on dosing 
in hepatic impairment. Similarly, this was carried out for 
end-stage renal disease and RRT/dialysis. To date, there is 
little published on the use of these agents in COVID-19 in 
renal and hepatic impairment. Active clinical trials in liver 
and kidney disease were identified using the above search 
terms on ClinicalTrials.gov and in the Chinese Clinical Trial 
Registry. As many of the primary medications have been 
repurposed, the majority of data for this article came from 
separate searches that were carried out for each therapeu-
tic agent with search terms of liver impairment, cirrhosis, 
end-stage renal disease and dialysis. The summary of prod-
uct characteristics (SmPC) from the European Medicines 
Agency (EMA), the Prescribing Information from the US 
Food and Drug Administration (FDA), renal drug handbook 
[22], LiverTox [23] and MicroMedex [24] were significant 
sources of information for this review.
3  Repurposed Treatments
The pharmacokinetic parameters of the repurposed treat-
ments are summarised in Table 1.
3.1  Dexamethasone
Dexamethasone is a glucocorticoid used in the treatment of 
a variety of inflammatory and autoimmune conditions. It is 
used at a wide range of doses, licensed from 0.5 to 80 mg 
daily, and is normally administered either orally or intrave-
nously [25]. It is used in COVID-19 dosed at 6 mg daily for 
10 days, either orally or intravenously [26].
3.1.1  Renal Recommendations
Dexamethasone is metabolised in the liver and 65% of the 
unchanged drug is eliminated renally within 24 h. Workman 
et al. [27] found similar dexamethasone pharmacokinetics 
for patients with normal renal function and chronic renal 
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failure. Another study [28] observed increased clearance 
and shortened elimination half-life, thought to be secondary 
to decreased protein binding of dexamethasone in uraemia 
[29]. High doses of dexamethasone such as 40 mg daily for 
4-day cycles are used safely in the treatment of multiple 
myeloma, a condition often associated with significant renal 
dysfunction [30]. No dose adjustment is recommended for 
patients with renal impairment, although frequent patient 
monitoring is advised in the product licence [25]. Dexameth-
asone pharmacokinetics do not appear to be significantly 
impacted by RRT and it may be used at the same dose as in 
normal renal function in this setting [22] (Table 2).
3.1.2  Hepatic Recommendations
Other glucocorticoids, including prednisolone, are used 
regularly for patients with significant liver disease in the 
treatment of autoimmune and alcoholic hepatitis, including 
for patients with cirrhosis, acute liver failure, ALT/AST > 
10× ULN and post-liver transplant [31, 32]. Dexamethasone 
is metabolised in the liver via CYP3A4 [33]. The licence 
for dexamethasone contains no specific recommendation 
for dosing in hepatic impairment, although it states that 
the elimination half-life is prolonged in severe liver disease 
[25]. Glucocorticoids can be associated with hepatic adverse 
effects; when used for long periods of time they can cause 
hepatic enlargement and steatosis. Given the low dose (6 mg 
daily) and short duration, this is unlikely to be significant 
when treating patients with COVID-19. No dose adjustment 
is required (Table 3).
3.2  Atazanavir and Atazanavir/Ritonavir
Atazanavir is a protease inhibitor licensed either alone at a 
dose of 400 mg or in combination with the pharmacokinetic 
booster ritonavir at a dose of 300/100 mg for the treatment 
of HIV infection, which is also the recommended dose in 
COVID-19 treatment [34, 35].
3.2.1  Renal Recommendations
Since atazanavir undergoes minimal renal elimination, the 
standard dosages of 300/100 mg or 400 mg (unboosted) can 
be used in patients with renal impairment [36]. Previously 
it was reported that exposure in patients undergoing hae-
modialysis was decreased by 30–50% [35]. However, one 
case report described comparable clearance in patients with 
and without dialysis [37]. In view of the limited data avail-
able, and the potential for increased atazanavir clearance 
during haemodialysis, boosted atazanavir may be preferred 
to achieve adequate exposure in patients undergoing RRT.
3.2.2  Hepatic Recommendations
Atazanavir is primarily hepatically metabolised and 
increased plasma concentrations are observed in patients 
with hepatic impairment [34, 35]. The majority of clini-
cal studies carried out in patients with advanced liver dis-
ease have been with unboosted atazanavir as exposure is 
increased in patients with impaired hepatic function, negat-
ing the need for boosting. The impact of moderate to severe 
hepatic impairment on atazanavir pharmacokinetics (without 
ritonavir) was evaluated in 16 patients with advanced liver 
disease (14 CPT B and 2 CPT C patients) after a single 
atazanavir 400-mg dose. The mean area under the plasma 
concentration curve (AUC) was 42% higher and mean half-
life increased (12.1 h vs 6.4 h) in patients with hepatic 
impairment compared with healthy volunteers [35]. In a 
study of similar size (10 CPT B and 5 CPT C patients) fol-
lowing atazanavir 400 mg daily, median AUC and minimal 
plasma concentration (Cmin) values were similar to those 
in historical controls. Interpatient variability in AUC was 
high although most of the patients were also on concomitant 
tenofovir and/or acid-suppressing therapy, factors that will 
also affect exposure [38]. As atazanavir is an inhibitor of 
UGT1A1, physicians should be aware of increased bilirubin 
concentration; however, this does not affect liver function 
and liver function markers [39].
The recommendation is to use unboosted atazanavir at 
a dose of 400 mg daily in mild hepatic impairment with a 
reduction to 300 mg in moderate hepatic impairment. Ataza-
navir is not recommended by the manufacturer in severe 
hepatic impairment [35], although data from several small 
studies is reassuring. Large interpatient variability in ataza-
navir exposure has been observed [40]. Considering this, 
along with the short duration of therapy used for COVID-19, 
the impact of any increased atazanavir exposure is unlikely 
to be clinically significant. However, raised serum bilirubin 
concentrations strongly correlate with increased atazanavir 
concentrations [40]. Thus, we recommend that atazanavir 
can be considered in severe hepatic impairment (300 mg 
once daily) if clinical benefit is likely to outweigh the poten-
tial risk, with close monitoring of hepatic function during 
treatment.
3.3  Lopinavir/Ritonavir
Similar to atazanavir, lopinavir is a protease inhibitor given 
with the pharmacokinetic booster ritonavir as a fixed-dose 
tablet, licensed for HIV treatment. In adults, the recom-
mended dose is 400/100 mg twice daily [41], which is also 
the dose used in COVID-19 treatment [42].
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3.3.1  Renal Recommendations
Approximately 10.4% of lopinavir is renally cleared, of 
which 2.2% is the unchanged drug [41, 43]. Therefore, no 
dose adjustments are needed in patients with renal impair-
ment. Gupta et al. [44] studied exposure of lopinavir/rito-
navir in 13 patients undergoing haemodialysis and reported 
that the AUC and maximal plasma concentration (Cmax) were 
comparable with historical controls. The Cmin was lower than 
expected (44% decrease). However, the authors concluded 
that twice daily dosing would maintain adequate Cmin levels. 
We recommend that lopinavir/ritonavir 400/100 mg twice 
daily can be prescribed in patients undergoing RRT.
3.3.2  Hepatic Recommendations
Lopinavir/ritonavir is mainly hepatically cleared with 82.6% 
excreted in the faeces, 19.8% as unchanged drug [41]. It 
has not been studied in severe hepatic impairment and its 
use is contraindicated [41, 43]. Lopinavir/ritonavir pharma-
cokinetics were studied in patients with mild (n = 6) and 
moderate (n = 6) hepatic disease. Lopinavir pharmacokinet-
ics were similar in both, with Cmax and AUC increased by 
20% and 30%, respectively, compared with HIV-1-infected 
subjects with normal hepatic function. The effect of hepatic 
impairment on low-dose ritonavir, however, showed phar-
macokinetic changes were more pronounced in the moderate 
impairment group (181% and 221% increase in AUC and 
Cmax, respectively) than in the mild impairment group (39% 
and 61% increase in AUC and Cmax, respectively) [45]. In 
severe hepatic impairment it is likely to have further signifi-
cantly increased exposure and would not be recommended 
due to risk of hepatotoxicity even with short durations, 
largely due to the presence of ritonavir twice daily.
No dose reduction is needed in mild to moderate hepatic 
impairment; however, frequent monitoring of LFTs would 
be recommended.
3.4  Remdesivir
Remdesivir is a nucleotide analogue with broad-spectrum 
antiviral activity. In vitro it is effective against filoviruses 
and coronaviruses. Remdesivir is metabolised to the phar-
macologically active nucleoside triphosphate metabolite 
(GS-441524). The recently available FDA and EMA pre-
scribing information describe remdesivir to have linear phar-
macokinetics, with remdesivir and GS-441524 being mainly 
renally excreted—49% and 10%, respectively, which is 74% 
of the total administered dose [46–48]. There is limited data 
available about the pharmacokinetics of remdesivir or dos-
ing in special populations.
Prior to obtaining the licence, remdesivir was used as 
part of a compassionate use programme or via clinical trials 
for the treatment of COVID-19 [49], with patients treated 
for 10 days intravenously (200 mg loading dose followed 
100 mg daily). Remdesivir was granted an Emergency Use 
Authorization (EUA) by the FDA on 2 May 2020 for treat-
ment of patients hospitalised with COVID-19 [47], followed 
by a full FDA licence on 22 October 2020. On 6 July 2020, 
the EMA granted an EUA [48].
3.4.1  Renal Recommendations
Both EU and US licences state remdesivir should not be 
used in patients with estimated glomerular filtration rate 
(eGFR) < 30  mL/min. Remdesivir is formulated with 
sulfobutylether-β-cyclodextrin sodium salt (SBECD), which 
has reduced clearance and therefore accumulates in patients 
with renal impairment. Hoover et al. previously studied the 
accumulation of SBECD in patients with renal impairment 
and although it accumulates, its safety and toxicity profile 
seem unaffected [50]. In addition, it could also be that the 
main metabolite (GS-441524) accumulates in patients with 
eGFR < 30 mL/min as it is mainly renally cleared. Cur-
rently, there are no case reports or safety data in patients 
with eGFR < 30 mL/min and only limited data on the safety 
of the co-formulated sodium salt that accumulates in renal 
impairment; therefore, no recommendations can be made for 
use in these populations (see Table 1).
3.4.2  Hepatic Recommendations
The pharmacokinetics of remdesivir have not been evaluated 
in patients with hepatic impairment. However, it is shown 
that only 18% of the administered dose is recovered in fae-
ces [47]. Remdesivir should not be commenced in patients 
with ALT ≥ 5 × ULN at baseline. It should be discontinued 
if ALT rises to ≥ 5 times ULN during treatment, although 
it can be restarted if ALT normalises [47]. Consideration 
should be given to stopping remdesivir if ALT elevation 
is accompanied by signs or symptoms of liver impairment. 
In study GS-US-540-5773 in 397 subjects with severe 
COVID-19 treated with remdesivir for 5 (n = 200) or 10 
days (n = 197), 19/385 (5%) had grade 3 liver abnormali-
ties and 9/385 (2%) had grade 4 [47] found during treat-
ment. In the absence of contraindications and because it is 
mainly renally cleared, no dose change is advised at present 
in patients with hepatic impairment, but treatment should be 
reviewed on a case-by-case basis with advice from specialist 
hepatologists considered.
3.5  Favipiravir
Favipiravir is an antiviral drug registered in Japan with 
activity against coronaviruses. Favipiravir has extensive 
metabolism to two metabolites; M1 is mainly formed by 
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aldehyde oxidase and xanthine oxidase and M2 is a glu-
curonide. Favipiravir used for the treatment of influenza is 
dosed at 1600 mg twice daily on Day 1, followed by 600 mg 
twice daily on Days 2–5 [51, 52]. For COVID-19 treatment, 
favipiravir is studied in different dosages varying from a 
maintenance dose of 200–600 mg twice daily for 10 days, 
with different loading dosages of 1600, 1800, and 2400 mg 
[51, 53].
3.5.1  Renal Recommendations
Favipiravir is mainly renally excreted (90.5%), of which the 
majority exists as M1 (82.0–92.4%). In the global phase III 
study, no patients with eGFR < 30 mL/min were included, 
one patient with eGFR 30–50 mL/min was included and 
there were 30 patients with eGFR 50–80 mL/min [51]. No 
PK data about the group of patients with eGFR 50–80 mL/
min is reported. The label states M1 is increased 2.5 times 
in patients with moderate renal impairment; however, this 
is based on the clearance of favipiravir in one patient. Any 
toxicity of favipiravir is likely related to M1, as it accumu-
lates in patients with renal impairment. However, no data is 
available to make any statement of safety in patients with 
renal impairment or dependent on RRT.
The manufacturer cites non-clinical pharmacokinetic 
data from the toxicity studies showing no observed adverse 
effects. They state it is unlikely that severe events would 
occur due to increased M1 levels; however, this is just based 
on data in one patient.
In addition, favipiravir increases uric acid levels in urine, 
which should be further investigated in patients with renal 
impairment; this is described in Mishima et al., 2020 [54]. In 
the phase III study, with a short treatment duration similar to 
use in COVID-19, adverse events in total occurred in 13/30 
(43.4%) patients with mild renal impairment and in 110/363 
(30.3%) patients with normal renal function. Overall, there 
is not enough data to recommendation use for patients with 
renal impairment or RRT [52].
3.5.2  Hepatic Recommendations
There has been one human study of favipiravir that looked 
specifically at hepatic impairment, clinical trial US109 [55]. 
Doses were reduced in severe hepatic impairment (CPT C). 
Mild and moderate hepatic impairment (CPT A and CPT 
B) resulted in 2.1- and 2.0-fold increases in favipiravir 
exposures, respectively, following single doses on Day 1. 
Severe hepatic impairment resulted in a 3.7-fold increase 
in total systemic exposure on Day 1, and 6.3- and 2.1-fold 
increases in AUC 0–12 and peak exposure, respectively, fol-
lowing multiple oral doses on Day 3. Mean half-life (t½) 
values of favipiravir were generally longer in subjects with 
mild, moderate and severe hepatic impairment compared 
with healthy volunteers. Approximately 45.4%, 44.1% and 
45.8% of the total favipiravir dose was recovered as the M1 
metabolite in urine in subjects with mild, moderate and 
severe hepatic impairment, respectively, compared with 
58.3%, 63.2% and 75.1% recovered from their respective 
healthy matches. Another recent study looked at treatment 
in CPT A patients with COVID-19 [56]. Despite earlier find-
ings, dosing in CPT A patients was comparable for those 
with normal hepatic function. This study will provide infor-
mation on whether increases in exposure in hepatic impair-
ment could be an issue.
Previously, no effects on the liver were observed in mon-
keys treated with favipiravir for 6 weeks at a dose equivalent 
to above the maximum exposure in humans. In consideration 
of these results and currently available clinical data, the use 
of favipiravir in patients at the proposed dosage regimen and 
possible increases in exposure is unlikely to have serious 
effects on the liver [52]. Based on these in vitro findings, we 
recommend the doses from the original healthy volunteer 
study [55] as detailed in Table 3 with duration to 14 days 
in CPA patients as per ongoing study in COVID-19 in this 
patient group. Extension beyond 5 days can be considered 
in CPT B and CPT C patients.
3.6  Hydroxychloroquine
Hydroxychloroquine and chloroquine are antiviral/immune 
modulators that are used for the treatment and prophylaxis 
of malaria, rheumatoid arthritis, lupus erythematodes, photo 
dermatosis and liver amoebiasis. Since chloroquine was only 
used in early COVID-19 studies we are not considering it 
in this review. As of November 2020, there remains 101 
actively recruiting studies on hydroxychloroquine on Clini-
calTrials.gov and despite some published data, it remains the 
most studied drug for COVID-19, particularly in resource-
poor countries as it is cheap and readily available. Hydroxy-
chloroquine dosages begin at 400–600 mg/day, followed by 
daily dosages of 200–400 mg. For COVID-19 treatment, 
high dosing regimens have been used, with the mean dose 
studied being 596 mg [57] as well as prophylactic [58] dos-
ages of 100 mg/day or 300 mg/week [26, 59, 60].
3.6.1  Renal Recommendations
Hydroxychloroquine has a very large volume of distribution 
with extreme accumulation in cells and tissues and a long 
elimination half-life. Jallouli et al. [61] studied 22 patients 
with systemic lupus erythematosus and chronic renal insuf-
ficiency (median serum creatinine clearance 52 mL/minute 
(range 23–58 mL/minute) who received 400 mg/day hydrox-
ychloroquine. The median blood concentration was signifi-
cantly higher than in patients with normal renal function 
(n = 509): 1338 ng/mL (range 504–2229 ng/mL]) versus 
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917 ng/mL (range 208–3316 ng/mL) but was still considered 
within the therapeutic window (high normal). Hydroxychlo-
roquine does not appear to be dialysed. Plasma concentra-
tions before and after dialysis were not significantly altered 
and hydroxychloroquine was not detected in the dialysate in 
three patients on dialysis (all on hydroxychloroquine therapy 
for at least 6 months) [61]. The FDA drug label states that no 
dose adaptations should be made in patients with impaired 
renal function as there is no correlation between creatinine 
clearance and renal clearance of hydroxychloroquine [62]. 
Therefore, patients with renal impairment and on RRT can 
be treated with standard-dose hydroxychloroquine without 
dose adjustment. It is recommended to monitor (short term) 
cardiotoxicity (i.e. QT prolongation).
The studies cited above were mainly done because of the 
severe long-term toxicity associated with hydroxychloro-
quine [63]. Retinopathy and cardiomyopathy risk increase 
in patients with chronic kidney disease, likely potentiated 
with longer term use. These toxicities are less likely to occur 
with COVID-19 treatment of only 5–14 days but may be 
of importance if hydroxychloroquine is used as prophylaxis 
for COVID-19. A risk–benefit analysis should be consid-
ered due to possible severe toxicity. These recommendations 
reflect guidance on short-term treatment courses.
3.6.2  Hepatic Recommendations
Hydroxychloroquine is metabolised by several CYP 
enzymes in the liver with desethylhydroxychloroquine being 
an active metabolite. SmPC and FDA prescribing informa-
tion caution use in patients with existing liver disease and/or 
concomitant use with hepatotoxic drugs [62, 64]. Hydroxy-
chloroquine is known to accumulate in the liver [65] and 
animal studies have shown that accumulation occurs rapidly 
in the first 2 weeks of treatment [66]. However, in a study 
by Tett et al. [67], hydroxychloroquine was found to have 
a low hepatic extraction ratio, indicating that a reduction 
in liver blood flow in cirrhosis may not directly result in 
increased exposure to the drug. Hydroxychloroquine is also 
known to be hydrophilic [68] and this should be a considera-
tion in patients with ascites and decompensated cirrhosis. 
The manufacturer recommends that consideration should be 
given to dose reduction with or without estimation of plasma 
levels to guide dosing [64]; however, therapeutic drug moni-
toring is unlikely to have utility in the context of COVID-19 
treatment. The American College of Rheumatology recom-
mendations contraindicate the use of hydroxychloroquine in 
CPT C liver disease [69]; again, these recommendations are 
made with the assumption of longer-term dosing.
In summary, despite risks that accumulation in liver may 
be reduced in the setting of COVID-19 treatment due to 
the short treatment length, the cautions and risks for use 
in hepatic impairment suggest that hydroxychloroquine is 
not a preferred agent in this patient population. If treatment 
was to proceed, a conservative approach may be to use a 
loading dose with a reduction of 50% for maintenance dos-
ing in patients with advanced liver disease (CPT C) and a 
maximum of no more than 400 mg per day. Other risks for 
toxicities such as concomitant QT prolongation drugs may 
also indicate need for dose reduction in patients with mild/
moderate liver disease. Baseline monitoring of liver func-
tion is required [70] and ongoing monitoring of toxicities 
is essential.
3.7  Azithromycin
Azithromycin is a macrolide antibiotic licensed for use in 
treatment of various infections such as community-acquired 
pneumonia, bronchitis, soft tissue infections and uncompli-
cated genital infections due to Chlamydia trachomatis and 
Neisseria gonorrhoeae. Doses used are in the range of 1 g 
as a single dose to 500 mg once daily for 3 days. To date, in 
COVID-19 it continues as an arm in many multi-centre clini-
cal trials, including RECOVERY, at doses of 500 mg daily 
on Days 1–5 or reducing to 250 mg daily for Days 2–5 [26].
3.7.1  Renal Recommendations
Azithromycin undergoes minimal renal elimination (6% 
unchanged following oral dosing, 11–14% unchanged fol-
lowing IV administration) [24]; the standard doses can be 
used in renal impairment. However, in severe renal impair-
ment (GFR < 10 mL/min), it has been noted that there is 
increased exposure by 33–35% and therefore caution is 
advised. For patients undergoing haemodialysis or con-
tinuous veno-venous haemofiltration, the dialysability of 
azithromycin is unknown and it is known not to be removed 
in peritoneal dialysis. Therefore, standard doses can be used, 
proceeding with caution and monitoring for adverse effects, 
such as QT prolongation.
3.7.2  Hepatic Recommendations
The liver is the main site for metabolism of azithromycin 
and 50% is excreted unchanged in the bile, although some 
inactive metabolites are also found [24]. Azithromycin is 
known to rarely cause acute liver injury, often manifested 
as a self-limiting cholestatic hepatitis. Any appearance of 
jaundice or other liver dysfunction should lead to a prompt 
discontinuation of azithromycin [23, 71].
Azithromycin is not recommended in severe liver disease 
due to significant hepatic metabolism and the liver being 
the principal route of elimination. Mazzei et al. [72] found 
that pharmacokinetics did not differ significantly in patients 
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with CTP A or B cirrhosis and therefore standard doses can 
be used in these patient groups. Dosing in CPT C patients, 
given the short courses used in COVID-19, could be consid-
ered with special hepatology input and monitoring of QTc 
prolongation.
3.8  Ribavirin
Ribavirin is a guanosine nucleoside analogue, approved 
for use in combination with direct acting antivirals or 
pegylated-interferon 2a or 2b for treatment of hepatitis 
C. In the treatment of hepatitis C, ribavirin is given orally 
and is dosed dependent on weight, ranging from 800 mg 
to 1200 mg daily in divided doses. In COVID-19, several 
ribavirin dosages are studied: 500 mg twice or three times 
daily intravenously or orally 400 mg twice daily in com-
bination with lopinavir/ritonavir [73, 74].
3.8.1  Renal Recommendations
Ribavirin has been extensively studied and used in patients 
with impaired renal function. As ribavirin is primarily 
renally cleared (62%), drug exposure and related toxicities 
(anaemia) increase with declining renal function. Anae-
mia should be taken into account when choosing the dose 
(with low baseline haemoglobin, a reduced dose might be 
Table 2  Overview of dose recommendations in patients with renal impairment
For eGFR, use Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula; the abbreviated Modification of Diet in Renal Disease 
(aMDRD) or the Cockcroft-Gault (CG) equation may be used as an alternative; see https ://www.chip.dk/Tools -Stand ards/Clini cal-risk-score s)
CVVH continuous veno-venous haemofiltration, eGFR estimated glomerular filtration rate, PD peritoneal dialysis, Vd volume of distribution
Drug Renal Impairment Renal Replacement Therapy Comments References
eGFR > 
50 mL/
min
eGFR 
30–50 mL/
min
eGFR 
10–30 mL/
min
eGFR < 
10 mL/min
Haemodi-
alysis
CVVH PD
Dexametha-
sone
100% 100% 100% 100% 100% 100% 100% [22, 25]
Atazanavir 
OR
Atazanavir/
ritonavir
100% 100% 100% 100% 100% 100% 100% [34–36]
Lopinavir/
ritonavir
100% 100% 100% 100% 100% 100% 100% [36, 41, 43]
Remdesivir 100% 100% Not recom-
mended
Not recom-
mended
Not recom-
mended
Not recom-
mended
Not recom-
mended
[47]
Favipiravir 100% No dose 
recom-
mendation 
possible
No dose 
recom-
mendation 
possible
No dose 
recom-
mendation 
possible
No dose 
recom-
mendation 
possible
No dose 
recom-
mendation 
possible
No dose 
recom-
mendation 
possible
[52]
Hydroxy-
chloro-
quine 
(short 
term)
100% 100% 100% 100% 100% 100% 100% Toxicity 
should be 
dose limit-
ing
[62, 64]
Azithromy-
cin
100% 100% 100% 100% with 
caution
100% with 
caution
100% with 
caution
100% with 
caution
[22, 71, 108]
Ribavirin 100% Alternating 
200–
400 mg 
every other 
day
200 mg daily 200 mg daily 200 mg daily 200 mg daily 200 mg daily Be aware of 
anaemia
[75, 76]
Interferon 
β-1a
100% 100% 100% Use with 
caution
Use with 
caution
Use with 
caution
Use with 
caution
Monitor 
renal func-
tion during 
treatment
[80, 81]
Tocilizumab 100% 100% 100% 100% 100% 100% 100% [22, 83, 84]
Anakinra 100% 100% 100% every 
other day
100% every 
other day
100% every 
other day
100% every 
other day
100% every 
other day
[88, 89]
Sarilumab 100% 100% 100% 100% 100% 100% 100% [96]
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indicated) [75, 76]. Ribavirin is not cleared by haemodialysis 
[75]. Dose reductions are required for patients with impaired 
renal function and for those on RRT and these recommenda-
tions are outlined in Table 2.
3.8.2  Hepatic Recommendations
In single-dose control studies, no difference in pharmacoki-
netic parameters were noted when administered in patients 
with liver dysfunction classed by CPT score A, B or C [75]. 
Much of the use of ribavirin is in patients with underlying 
liver disease and it is not associated with liver injury. How-
ever, it is associated with a dose-dependent red cell hae-
molysis which can be accompanied by a mild increase in 
indirect bilirubin. In general, this effect is usually benign and 
resolves quickly on cessation of ribavirin [23, 77]. Full-dose 
ribavirin can be used in CPT A with caution and in CPT B 
and CPT C with appropriate dose reduction based on eGFR 
if there is assocated renal impairment.
3.9  Interferon‑β
Interferon-β is produced by recombinant technology and is 
a cytokine with antiviral, immunomodulatory and antipro-
liferative properties. Interferon-β is available as 1a and 1b 
and pegylated β-1a. The letter identifies the placement of 
amino acid sequences at positions 1 and 17 and indicates if 
glycosylation is present [24]. Interferon-β is approved for use 
in multiple sclerosis where all of these preparations are used 
by either subcutaneous or intramuscular administration. In 
COVID-19 clinical trials, it has been used in both nebulised 
and intravenous forms [26, 60].
3.9.1  Renal Recommendations
It is estimated that approximately 40% of interferon-β is 
excreted renally. Increased exposure of interferon-β may 
be expected, particularly in severe renal impairment, which 
may increase the risk of dose-related adverse effects such 
as myelosuppression or hepatotoxicity [78]. The interferon 
molecule is too large to be dialysed and will not undergo 
renal degradation. In patients with severe renal dysfunction 
or those on RRT, it is recommended to use interferon-β with 
caution, with monitoring of renal function [22].
3.9.2  Hepatic Recommendations
Hepatic dysfunction has been noted in patients treated with 
interferons for prolonged courses for indications such as 
multiple sclerosis [79]. This dysfunction is usually seen 
as asymptomatic increase in liver enzymes, although rare 
cases of fulminant liver failure have been noted with mecha-
nism of injury not known [23]. Therefore, the commercially 
available products advise caution for use in patients with 
established hepatic disease, chronic alcohol misuse and/or 
baseline increase in ALT (2.5 × ULN). Baseline and contin-
ued monitoring of transaminases is advised, and dose reduc-
tions are advised if ALT increased by 5 × ULN. Treatment 
should be discontinued if the patient develops jaundice or 
clinical symptoms of liver disease [80, 81].
In treatment of COVID-19 where short finite courses are 
proposed, interferon-β could be used with caution in patients 
with a baseline increase in serum ALT above 2.5 × ULN 
and after a careful assessment of balance of risks versus 
benefits if ALT is >5 × ULN. Prescribing could be consid-
ered in patients with established cirrhosis (CPT A) but use 
in decompensated cirrhosis is not advised.
3.10  Tocilizumab
Tocilizumab is an anti-human IL-6 receptor monoclonal 
antibody (mAb) approved for the treatment of rheumatoid 
arthritis and systemic juvenile idiopathic arthritis. Patients 
infected with COVID-19 experience an elevation of IL-6 
(cytokine storm). It is usually dosed between 4 and 12 mg/
kg every 2 or 4 weeks depending on indication, and is being 
studied for COVID-19 at 4- to 8-mg/kg single doses, with 
one additional dose if clinically indicated [60, 82]. As of 
November 2020, despite varying reports of beneficial effect, 
tocilizumab remains an active arm in many global clinical 
trials.
3.10.1  Renal Recommendations
Tocilizumab is not metabolised or excreted by the kidneys, 
instead it is broken down into peptides and amino acids and 
recycled, comparable with IgG; therefore, it is not expected 
to be affected by reduced renal function. No formal registra-
tion studies were conducted for renal impairment, although 
pharmacokinetics were not different in patients with mild 
renal impairment (creatinine clearance between 50 and 
80 mL/min) [83, 84]. In addition, the large molecular weight 
of tocilizumab prevents clearance via glomerular filtration or 
RRT [85]. Based on this knowledge, no dose reductions are 
necessary in patients with impaired renal function or RRT.
3.10.2  Hepatic Recommendations
Tocilizumab has not been studied in patients with hepatic 
impairment, but it is expected to have minimal hepatic 
metabolism. No recommendations are in the label regarding 
dose adjustments in patients with established liver disease.
Tocilizumab may cause hepatoxicity reversible on 
discontinuation and should be used in caution in the set-
ting of COVID-19 in those already presenting with acute 
liver injury. A total of 4171 patients on tocilizumab were 
 F. Marra et al.
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evaluated in the setting of rheumatoid arthritis and ALT and 
AST elevations greater than the ULN occurred in 70.6% 
and 59.4% of patients, respectively, and > 5 × ULN in 2.9% 
and 0.9% of patients. Most elevations occurred during the 
first year of treatment [86]. The authors acknowledge the 
significantly shorter course used in COVID-19; however, 
close monitoring of LFTs are recommended for any patient 
starting tocilizumab where baseline transaminases are > 1.5 
× ULN. The manufacturer recommends withholding treat-
ment if LFTs rise beyond 3 × ULN, and to discontinue if 
they rise beyond 5 × ULN [83, 84].
mAbs have been thought not to be affected by chronic 
hepatic impairment due to their alternative metabolism. 
However, in a review of the pharmacokinetics of mAbs in 
hepatic impairment considering the available data from drug 
licences, published studies and pharmacokinetic modelling, 
Sun et al. [87] found a small amount of reduced drug expo-
sure for some mAbs in patients with mild hepatic impair-
ment, and a more significant reduction in exposure in mod-
erate hepatic impairment. No specific data was found for 
tocilizumab and disease severity was not fully described, 
where we know that clearance of mAbs is higher in patients 
with more severe disease or lower albumin. More studies are 
required to explore this concept.
In summary, it is difficult to make a recommendation on 
the dosing of tocilizumab in chronic hepatic impairment. 
As there is no pharmacokinetic data available, it is unclear 
whether there is the potential for altered drug exposure, 
whilst there is also a risk of drug-induced hepatic injury. If 
use is considered necessary in hepatic impairment, consider 
using a full dose, provided AST and ALT are not signifi-
cantly deranged (e.g. not > 2 × ULN) and the patient is not 
thrombocytopenic.
3.11  Anakinra
Anakinra is an analogue of the human IL-1 receptor antago-
nist. It blocks the activity of IL-1 by competitively inhibiting 
IL-1 binding to the IL-1 type I receptor (IL-1RI), which is 
expressed in a wide variety of tissues and organs. It is used 
in the treatment of rheumatoid arthritis and other inflam-
matory conditions. For rheumatoid arthritis, it is dosed at 
100 mg/day subcutaneously, and 1–2 mg/kg/day in most 
other conditions [88, 89]. It is being investigated at a vari-
ety of doses for COVID-19, including 5 mg/kg twice daily 
intravenously, 100 mg 6-h intravenously after a 300 mg load-
ing dose, and 100 mg subcutaneously once or twice daily 
[90, 91].
3.11.1  Renal Recommendations
Yang et  al. [92] studied anakinra pharmacokinetics in 
patients with different stages of renal disease, including BD
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patients on RRT. They described the clearance of anak-
inra to be directly related to renal function and that dialy-
sis (continuous ambulatory peritoneal dialysis/haemodi-
alysis [CAPD/HD] < 2.5%) did not remove anakinra. They 
simulated every-other-day dosing and suggested that this 
might be appropriate for these patients. Comparable data is 
described in the drug label showing that subjects with eGFR 
50–80 mL/min and eGFR 30–49 mL/min had reduced clear-
ance of 16% and 50%, respectively. In addition, patients with 
eGFR < 30 mL/min and end-stage renal disease had declined 
clearance of 70% and 75%, respectively. For patients with 
an eGFR >30 mL/min, 100% of the dose is recommended 
and for eGFR <30 mL/min, a reduction to the same dose 
administered on alternate days [88].
3.11.2  Hepatic Recommendations
Studies in hepatic impairment are limited. The safety and 
efficacy have not been studied in patients with AST or ALT 
of ≥1.5 × ULN. Twelve patients with moderate hepatic dys-
function (CPT B) were given a single 1-mg/kg intravenous 
dose and pharmacokinetic parameters were not substantially 
different from healthy volunteers [88]. Therefore, no dosage 
adjustment is required in patients with hepatic impairment, 
with caution recommended in patients with CPT C cirrhosis 
or those with ALT elevation.
3.12  Sarilumab
Sarilumab is a recombinant human monoclonal antibody 
that blocks the activity of pro-inflammatory cytokines via 
IL-6 receptors. It is used in the treatment of moderate to 
severe rheumatoid arthritis. The usual dosage is 200 mg 
every 2 weeks via subcutaneous injection. Sarilumab is 
being investigated for COVID-19 at 200-mg and 400-mg 
single doses [60, 93–95]. Less commonly, protocols may 
include a further dose 24–48 h after the initial dose.
3.12.1  Renal Recommendations
As with tocilizumab, sarilumab is broken down to peptides 
and amino acids via catabolic pathways rather than via 
renal or hepatic pathways. In patients with mild or moder-
ate renal impairment, pharmacokinetics of sarilumab were 
not affected. Patients with severe renal impairment were not 
reported in the drug label. No dose adjustment is recom-
mended in renal impairment [96].
3.12.2  Hepatic Recommendations
There is limited evidence available for treating patients with 
hepatic impairment with sarilumab. Treatment is commonly 
associated with a reversible liver enzyme derangement 
which in clinical studies did not result in clinically signifi-
cant hepatic injury. An ALT increase occurred in 48% of 
rheumatoid arthritis patients treated with sarilumab [97]. 
The licence recommends that it should not be initiated in 
patients with an AST or ALT > 1.5 × ULN [96]; however, 
as single doses are predominantly used in COVID-19, exclu-
sion criteria in most clinical trial protocols include ALT or 
AST > 5 × ULN [96].
As the drug label does not include patients with hepatic 
impairment, and no data have been reported for sarilumab in 
the review by Sun et al. [87] of mAbs in hepatic impairment, 
It is unclear whether there could be an alteration in drug 
exposure in patients with significant hepatic impairment. 
As a result, it is difficult to make a dosage recommenda-
tion in this population. If treatment is required in hepatic 
impairment, consideration should be given to using full-dose 
sarilumab provided that ALT and AST are not significantly 
elevated (e.g. not > 2 × ULN) and there is no significant 
thrombocytopenia. These parameters, as with all immune 
modulators, should be reviewed in the context of the critical 
care setting.
4  Discussion
Data suggests that liver disease appears to be a risk factor for 
mortality in hospitalised patients with COVID-19 [12]; this 
includes longstanding organ damage or acute onset. Several 
physiological changes occur in a cirrhotic liver affecting the 
process of drug handling. These include liver cell necrosis, 
portal shunting of the blood, reduced production of drug-
binding proteins (such as albumin and α1-acid glycopro-
tein, increasing unbound fractions of drug), abnormal drug 
volume of distribution, altered drug elimination and altered 
drug metabolism [4, 98]. Therefore, understanding detailed 
hepatic drug metabolism can provide a rationale for dos-
age adjustment in patients with hepatic impairment and the 
pharmacokinetic parameters of each drug were examined 
when making recommendations. Increased drug concentra-
tions in patients with liver disease may result from different 
mechanisms, many of which have not been properly studied 
in these repurposed medications and further data in these 
areas would be welcomed. These include decreased clear-
ance, increased absorption due to an altered vasculature 
around the stomach and intestines, or both. Associated renal 
failure and concomitant drug–drug interactions must also 
be considered, and it should be noted that liver disease not 
only affects pharmacokinetics but also pharmacodynamics, 
as with the worsening anaemia seen with ribavirin.
The impairment of drug metabolism is proportional to the 
degree of liver dysfunction, as illustrated with lopinavir/rito-
navir, where a 39% and 181% increase in ritonavir AUC is 
seen in mild and moderate hepatic impairment, respectively 
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[41]. Patients with compensated cirrhosis with normal syn-
thetic function are likely to have minimal impairment of 
drug metabolism compared with patients with decompen-
sated cirrhosis, and these recommendations reflect this. 
Despite this proportional effect, prescribing any drugs with 
potential hepatotoxicity in the cirrhotic population should 
be done with caution. Any drug-induced liver injury may 
precipitate hepatic decompensation in cirrhotic patients 
with previously normal synthetic function. A hepatologist 
should be consulted regarding the use of any of these medi-
cations in a patient with advanced liver disease. Addition-
ally, it is important to consider drug–drug interactions [19] 
when instituting any treatment in liver transplant recipients 
with COVID-19. Despite the complexities associated with 
hepatic impairment, and the absence of data, particularly in 
advanced liver disease, these recommendations acknowledge 
the likely decreased risk of one-off or short-course dosing in 
COVID-19. Treatment decisions should be made on a case-
by-case basis in patients with decompensated liver disease, 
which even in the absence of COVID-19 is associated with 
high short-term mortality.
Compared with hepatic impairment, the changes occur-
ring in renal impairment are less complicated. Firstly, when 
the filtering capacity of the kidney decreases, drugs that 
are significantly dependent on renal clearance (glomerular 
filtration) will normally have decreased clearance resulting 
in higher plasma concentrations (unless there are any other 
compensatory clearance pathways). This is apparent with 
anakinra and ribavirin (predominantly renally cleared) where 
there is increased exposure as renal function decreases. Dose 
alterations are therefore required in these circumstances. An 
estimated glomerular filtration rate (eGFR) can be calculated 
using different equations such as Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) or Modification of 
Diet in Renal Disease (MDRD), although it is acknowledged 
that there are limitations here with respect to the elderly 
or obese, for example. Active tubular secretion and tubular 
reabsorption are also important for the renal clearance of 
drugs; however, these factors are not directly measured with 
eGFR.
Dialysis and other forms of RRT may be indicated in the 
COVID-19 population as previously mentioned. Flow, pore 
size of the membrane, and the characteristics of whether 
drugs are removed with dialysis or not were identified prior 
to making recommendations. Only unbound concentrations 
of small molecules can be dialysed and most biologics (due 
to being large proteins) are not dialysable. Additionally, 
water solubility and the volume of distribution are impor-
tant. For example, ribavirin is mainly trapped in the red 
blood cell and only a small part is unbound and available for 
dialysis. This unbound fraction is removed effectively with 
haemodialysis (50%); however, this is not clinically relevant 
as the drug remains available in another compartment [75].
Physiologically based pharmacokinetic modelling 
(PBPK) is a tool which can be used to better inform on dos-
ing recommendations in organ impairment. Anatomical, 
physiological and molecular changes related to liver and 
renal impairment have been quantitatively described and 
integrated into mechanistic pharmacokinetic modelling [99, 
100]. The application of PBPK models can support the pre-
diction of drug distribution in patients with various degrees 
of organ impairment and consequently allow the rational 
identification of suitable dosing regimens to avoid potential 
toxicities. The combination of multiple organ impairments 
can result in multifactorial effects on drug distribution that 
can complicate the application of PBPK modelling, which 
should be limited to scenarios that are fully characterised.
It should be noted that the majority of data obtained for 
this paper are from patients who did not have COVID-19. 
Dosages of repurposed antivirals that have been used in 
COVID-19 are largely based on exposure–response relation-
ships from other viruses such as HIV and influenza. Even 
without the current pandemic, data is limited in these spe-
cial populations who are often only studied in very small 
numbers, if at all. The presence of COVID-19 itself could 
independently influence the clearance and thus exposure 
(efficacy/toxicity) of drugs, and as yet there is minimal data 
in this context. In addition, COVID-19 patients admitted to 
the ICU that are acutely unwell will have altered pharma-
cokinetics, which has been well described in other critically 
ill patient populations with hepatic and renal dysfunction. 
Oxidative metabolism is the main clearance pathway for 
many prescribed medications and there is increasing recog-
nition of the importance of decreased activity of the hepatic 
cytochrome P450 system in critically ill patients [101]. 
Renal failure in critical care is of equal importance with both 
altered filtration and secretion clearance mechanisms affect-
ing the removal of parent drugs and their active metabolites. 
Use of repurposed therapies for COVID-19 in critical care 
should be carried out with particular caution.
5  Conclusion
There is growing evidence indicating hepatic and renal 
impairment, in both acute and chronic settings, are a com-
mon occurrence in the treatment of COVID-19. Dosing 
remains complex and often data is lacking even in drugs 
like hydroxychloroquine that have been in use for over 60 
years. These recommendations review all available data. 
Where dosing has been suggested for advanced liver or kid-
ney disease, often data is minimal, and prescribing should be 
undertaken in consultation with experienced hepatologists 
or nephrologists for these populations.
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